This is an aggregated industry headline. Read the full story at PharmaVoice →
Can pharma sustain its $2T trajectory?
GLP-1s will fuel the industry's growth in the coming years if outside forces don't get in the way.
By PharmaVoice
· Jul 2, 2026
· via PharmaVoice
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
The ad uses hand-crafted puppets to portray sight-based frustrations for those with presbyopia, a common condi…
The WeekFierceBiotech ↗
Roche's investigational KRAS G12C inhibitor has beaten Amgen's Lumakras and Bristol Myers Squibb's Krazati in …
The WeekBriefing
CMS is again proposing reduced Medicare payments for 340B drugs, reopening a long fight over hospital margins …